big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir)

February 2014

You'll see big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir).

Most patients currently get "triple therapy"...with interferon, ribavirin, plus an oral protease inhibitor (Incivek, Victrelis).

Now new drugs...including some in the pipeline...will make treatment easier, more effective, and better tolerated.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote